Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team.
Rossi C, et al. Among authors: binka m.
J Hepatol. 2019 Dec;71(6):1116-1125. doi: 10.1016/j.jhep.2019.07.021. Epub 2019 Aug 6.
J Hepatol. 2019.
PMID: 31433302